New Delhi:The Serum Institute of India has informed the Centre that it will be able to supply around 22 crore doses of Covishield in October as the Union government has announced resuming the export of surplus Covid vaccines in the coming fourth quarter under the 'Vaccine Maitri' programme, official sources said.
In a communication to the Centre on Monday, Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), said the firm has enhanced its production capacity of Covishield and it will be able to supply 21.90 crore doses in October to Government of India and private hospitals. The Pune-based pharmaceutical company has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month.
"Starting from January 2021, we have supplied 66.33 crore doses of Covishield to MoHFW, Government of India in addition to the supply of more than 7.77 crore doses to state governments and private hospitals till 19th September 2021 evening. All this has become possible under the dynamic leadership and kind direction of our Prime Minister Narendra Modi Ji, continuous support from team Ministry of Health and GoI, visionary leadership of our CEO, Dr Adar C Poonawalla, along with untiring efforts of Team SIIPL," a source quoted Singh as having communicated.
Singh further assured that by December 31, keeping with the timeline, the firm will complete the recent supply order of 66 crore doses. "At this juncture, I can assure you that by December 31, 2021, we will complete supply of 66 crore doses of Covishield against the recent order and will touch supplies of more than 130 crore doses of Covishield in the year 2021. We are working relentlessly to fulfil our prime minister's dream for successful completion of world's largest vaccination drive so that our country overcomes COVID-19 pandemic," the communication stated.
Read: Govt simplifies rules for transportation of medical oxygen
Union Health Minister Mansukh Mandaviya on Monday announced that India will resume export of surplus COVID-19 vaccines in the fourth quarter of 2021 under the 'Vaccine Maitri' programme and to meet its commitment to the COVAX global pool, but vaccinating its own citizens remains the topmost priority of the government.